Vault-13

Flagship Pioneering, LLC

CAMBRIDGE, MA · CIK 1400240 · 13F filing filed 2022-08-15

Exempt reporting adviser since 2012 · limited liability company

As an employer

$2.7bn reported value -37.7% vs Q1 2022
12positions
99.6%in top 10
0 new 1 added 1 reduced 1 sold out vs Q1 2022

This report includes the holdings of 7 other managers that share the investment decisions:

Shares in two reports are counted once in each security's totals.

Holdings, Q2 2022

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 MODERNA INC COM MRNA MRNA 12,886,743 $1.8bn69.35% 69.35% ReducedShares held: Q3 2021 17.6m, Q4 2021 17.6m, Q1 2022 17.6m, Q2 2022 12.9m -4.7m -4,694,273 -26.7%
2 SANA BIOTECHNOLOGY INC COM SANA SANA 34,239,018 $220.2m8.29% 8.29% UnchangedShares held: Q3 2021 34.2m, Q4 2021 34.2m, Q1 2022 34.2m, Q2 2022 34.2m
3 FOGHORN THERAPEUTICS INC COM FHTX FHTX 12,674,120 $172.4m6.49% 6.49% UnchangedShares held: Q3 2021 12.7m, Q4 2021 12.7m, Q1 2022 12.7m, Q2 2022 12.7m
4 EVELO BIOSCIENCES INC COM COM 50,427,328 $106.4m4.01% 4.01% AddedShares held: Q3 2021 23.0m, Q4 2021 23.0m, Q1 2022 23.0m, Q2 2022 50.4m +27.4m +27,397,259 119.0%
5 OMEGA THERAPEUTICS INC COMMON STOCK COMMON STOCK 25,902,269 $98.4m3.71% 3.71% UnchangedShares held: Q3 2021 25.9m, Q4 2021 25.9m, Q1 2022 25.9m, Q2 2022 25.9m
6 DENALI THERAPEUTICS INC COM DNLI DNLI 2,619,968 $77.1m2.90% 2.90% UnchangedShares held: Q3 2021 2.7m, Q4 2021 2.6m, Q1 2022 2.6m, Q2 2022 2.6m
7 SERES THERAPEUTICS INC COM COM 14,378,802 $49.3m1.86% 1.86% UnchangedShares held: Q3 2021 14.4m, Q4 2021 14.4m, Q1 2022 14.4m, Q2 2022 14.4m
8 AXCELLA HEALTH INC COM COM 18,867,785 $38.3m1.44% 1.44% UnchangedShares held: Q3 2021 12.5m, Q4 2021 12.5m, Q1 2022 18.9m, Q2 2022 18.9m
9 RUBIUS THERAPEUTICS INC COM RUBY RUBY 38,506,526 $32.7m1.23% 1.23% UnchangedShares held: Q3 2021 38.5m, Q4 2021 38.5m, Q1 2022 38.5m, Q2 2022 38.5m
10 SIGILON THERAPEUTICS INC COM COM 10,370,369 $8.6m0.32% 0.32% UnchangedShares held: Q3 2021 10.4m, Q4 2021 10.4m, Q1 2022 10.4m, Q2 2022 10.4m
11 CODIAK BIOSCIENCES INC COM CDAK CDAK 2,607,303 $7.5m0.28% 0.28% UnchangedShares held: Q3 2021 2.6m, Q4 2021 2.6m, Q1 2022 2.6m, Q2 2022 2.6m
12 SYROS PHARMACEUTICALS INC COM SYRS SYRS 2,938,494 $2.8m0.11% 0.11% UnchangedShares held: Q3 2021 2.9m, Q4 2021 2.9m, Q1 2022 2.9m, Q2 2022 2.9m

Sold out since Q1 2022

SecurityTickerShares held beforeValue then
KALEIDO BIOSCIENCES INC KLDO KLDO 19,575,710 $32.3m19.6m shares

Stakes above 5%

Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.

CompanyTickerStakeChange ScheduleLast filed
GENERATE BIOMEDICINES INC GENB · 13G · filed 2026-05-15 GENB 48.9%≈ $1.1bn new 13G 2026-05-15